首页> 美国卫生研究院文献>Journal of Clinical Microbiology >A Sensitive Multiplex Real-Time PCR Assay for Prospective Detection of Shiga Toxin-Producing Escherichia coli from Stool Samples Reveals Similar Incidences but Variable Severities of Non-O157 and O157 Infections in Northern California
【2h】

A Sensitive Multiplex Real-Time PCR Assay for Prospective Detection of Shiga Toxin-Producing Escherichia coli from Stool Samples Reveals Similar Incidences but Variable Severities of Non-O157 and O157 Infections in Northern California

机译:用于粪便样品中志贺毒素生产性大肠杆菌的前瞻性检测的灵敏多重实时PCR分析揭示了类似的发病率但在北加利福尼亚州的非O157和O157感染严重程度不同

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Rapid and accurate detection of Shiga toxin-producing Escherichia coli (STEC) of all serotypes from patients with diarrhea is critical for medical management and for the prevention of ongoing transmission. In this prospective study, we assessed the performance of a multiplex, real-time PCR assay targeting stx1 and stx2 for the detection of O157 and non-O157 STEC in diarrheal stool samples enriched in Gram-negative broth. We show that the assay is 100% sensitive (95% confidence interval [CI], 89.1% to 100%) and 98.5% specific (95% CI, 90.6% to 99.9%) based on a panel of 40 known STEC-positive specimens and 65 known negative specimens. During a 2-year postvalidation period, the assay detected more positive samples from patients in northern California than did culture and PCR testing performed at a public health reference laboratory, with a positive predictive value of 95.6% (95% CI, 87.6% to 99.1%). Serotyping data showed an incidence rate of 51.2% for non-O157 STEC strains, with 5.8% of patients (1/17) with non-O157 strains and 42.9% (6/14) with O157 strains (P = 0.03) developing hemolytic-uremic syndrome. The findings from this study underscore the recommendations of the CDC for laboratories to test all diarrheal stool samples from patients with acute community-acquired diarrhea for non-O157 STEC in addition to the O157 serotype by using a sensitive assay. Additionally, a survey of 17 clinical laboratories in northern California demonstrated that nearly 50% did not screen all stool specimens for the presence of Shiga toxins, indicating that many clinical microbiology laboratories still do not routinely screen all stool specimens for the presence of Shiga toxins as recommended in the 2009 CDC guidelines.
机译:快速和准确地检测出腹泻患者所有产志贺毒素的大肠杆菌(STEC)对于医疗管理和预防持续传播至关重要。在这项前瞻性研究中,我们评估了以stx1和stx2为靶标的多重实时PCR检测在检测富含革兰氏阴性肉汤的腹泻粪便样本中O157和非O157 STEC方面的性能。我们显示,根据一组40个已知的STEC阳性样本,该测定法具有100%的敏感性(95%置信区间[CI],89.1%至100%)和98.5%的特异性(95%CI,90.6%至99.9%)和65个已知的阴性标本。验证后的2年中,与在公共卫生参考实验室进行的培养和PCR检测相比,该检测方法在北加利福尼亚州的患者中检测出了更多阳性样品,阳性预测值为95.6%(95%CI,87.6%至99.1) %)。血清分型数据显示,非O157 STEC菌株的发生率为51.2%,非O157菌株的患者(1/17)为5.8%,而O157菌株(P = 0.03)的患者为42.9%(6/14)。尿毒症综合征。这项研究的结果强调了CDC对于实验室的建议,即通过使用敏感测定法,除了O157血清型外,还应对来自社区急性获得性腹泻的非O157 STEC患者的所有腹泻粪便样本进行测试。此外,对北加州17个临床实验室的调查显示,将近50%的人没有筛查所有粪便标本中是否存在志贺毒素,这表明许多临床微生物学实验室仍然没有常规筛查所有粪便标本中是否存在志贺毒素。在2009 CDC指南中推荐。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号